SS
BCTX

SBI Securities’s Briacell Therapeutics BCTX Stock Holding History

SBI Securities’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80
Closed -$880 – 4039
2025
Q3 		$880 Buy
80
+20
+33% +$210 ﹤0.01% 2749
2025
Q2 		$1.76K Hold
60
– – ﹤0.01% 2440
2025
Q1 		$2.19K Buy
60
+27
+82% +$1.29K ﹤0.01% 2249
2024
Q4 		$2.83K Buy
+33
New +$3.96K ﹤0.01% 2154

Other funds holding BCTX

FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SSA
SSA Swiss Advisors Zurich $266M AUM 24.57% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities's BCTX Position: Q4 2025 in Review

SBI Securities sold out of Briacell Therapeutics (BCTX) in Q4 2025, closing a stake of 80 shares — an estimated $880 sold.

SBI Securities first reported a position in BCTX in Q4 2024 and held it in 4 quarters. The position peaked at $2.83K in Q4 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q4 2025.

  • SBI Securities reported no remaining Briacell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 80 Briacell Therapeutics shares in Q4 2025, an estimated $880.
  • SBI Securities first reported a position in Briacell Therapeutics in Q4 2024 and held it in 4 quarters.
  • SBI Securities's Briacell Therapeutics position peaked at $2.83K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.